Company intelligence / Profile preview

Cytovation

Ownership: Private
Development stage: Phase 1

Overview

Cytovation’s lead candidate, CyPep‑1/CY‑101, has demonstrated a dual mode of action—directly lysing tumor cells and inducing an immune response through in situ vaccination. The company’s approach aims to overcome resistance mechanisms associated with the Wnt/β-catenin pathway. Early clinical data support safety and initial efficacy signals across multiple solid tumor types; further results are pending from ongoing trials targeting ACC, HCC, CRC, and other β-catenin-driven cancers.

Therapeutic areas: OncologyDermatology
Modalities: Synthetic peptides (notably bifunctional and engineered peptides)Immunotherapy agents
Industry: Biotech

Drug pipeline

1 asset

cypep-1

Beyond the preview

Go deeper on Cytovation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytovation.

Explore the full profile